Table 3 Anti-tumor effects of ACE inhibitors or ARBs in recent clinical studies
Authors (year), reference | Number of patients taking ACE inhibitors or ARBs | Medication | Type of cancer | Main findings |
|---|---|---|---|---|
Ronquist et al. (2004) [54] | 100 | ACE inhibitors | Prostate cancer | Current use of ACE inhibitors was not associated with decreased risk of prostate cancer (OR 0.9, 95 % CI 0.7–1.1) |
Sjoberg et al. (2007) [53] | 62 and 101 | ACE inhibitors | Esophageal and gastric cancer | Current use of ACE inhibitors did not decrease the risk of esophageal and gastric cancer (OR 0.79, 95 % CI 0.60–1.05 for esophageal cancer; OR 1.11, 95 % CI 0.88–1.39 for gastric cancer) |
Sipahi et al. (2010) [55] | 2510 | ARB | Any | Patients taking ARBs had a significantly increased risk of new cancer development (RR 1.08, 95 % CI 1.01–1.15; p = 0.016) |
Pasternak et al. (2011) [56] | 3954 | ARB | Any | ARB did not increase the risk of cancer (RR 0.99, 95 % CI 0.95–1.03) |
The ARB Trialists Collaboration (2011) [57] | 4549 | ARB | Any | There was no association between ARB usage and cancer incidence (OR 1.00, 95 % CI 0.95–1.04) |